| MeSH term | MeSH ID | Detail |
|---|---|---|
| Arteriolosclerosis | D050379 | 1 associated lipids |
| Tooth Ankylosis | D020254 | 1 associated lipids |
| Spondylarthropathies | D025242 | 1 associated lipids |
| Musculoskeletal Diseases | D009140 | 2 associated lipids |
| Hip Fractures | D006620 | 2 associated lipids |
| No-Reflow Phenomenon | D054318 | 2 associated lipids |
| Ossification, Heterotopic | D009999 | 2 associated lipids |
| Adrenal Hyperplasia, Congenital | D000312 | 2 associated lipids |
| Angina, Stable | D060050 | 2 associated lipids |
| Sarcoma, Ewing | D012512 | 2 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Machado do Reis L et al. | Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice. | 2008 | Bone | pmid:18499553 |
| Asaba Y et al. | Urinary gamma-glutamyltransferase (GGT) as a potential marker of bone resorption. | 2006 | Bone | pmid:16942925 |
| Kanzaki S et al. | Resorption of auditory ossicles and hearing loss in mice lacking osteoprotegerin. | 2006 | Bone | pmid:16564235 |
| Maddi A et al. | Long wave ultrasound may enhance bone regeneration by altering OPG/RANKL ratio in human osteoblast-like cells. | 2006 | Bone | pmid:16567138 |
| Mandelin J et al. | Human osteoblasts produce cathepsin K. | 2006 | Bone | pmid:16337236 |
| You L et al. | Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. | 2008 | Bone | pmid:17997378 |
| GarcÃa-Hernández A et al. | High glucose concentrations alter the biomineralization process in human osteoblastic cells. | 2012 | Bone | pmid:22086137 |
| Bougioukli S et al. | Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect. | 2016 | Bone | pmid:26723577 |
| Lee SK and Lorenzo JA | Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. | 2002 | Bone | pmid:12110442 |
| Kanematsu M et al. | Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway. | 2002 | Bone | pmid:11934645 |
| Li X et al. | Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. | 2002 | Bone | pmid:11934647 |
| Kostenuik PJ et al. | Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. | 2004 | Bone | pmid:15050896 |
| Brage M et al. | Osteoclastogenesis is decreased by cysteine proteinase inhibitors. | 2004 | Bone | pmid:15003789 |
| Fukunaga J et al. | Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. | 2004 | Bone | pmid:15003790 |
| Sato M et al. | New 19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 analogs strongly stimulate osteoclast formation both in vivo and in vitro. | 2007 | Bone | pmid:17070129 |
| Khoshniat S et al. | Phosphate-dependent stimulation of MGP and OPN expression in osteoblasts via the ERK1/2 pathway is modulated by calcium. | 2011 | Bone | pmid:21147284 |
| Wang QP et al. | Effects of 17β-estradiol on adiponectin regulation of the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand. | 2012 | Bone | pmid:22634178 |
| Wang FS et al. | Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. | 2007 | Bone | pmid:17055793 |
| Humphrey EL et al. | Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. | 2006 | Bone | pmid:16298558 |
| Horowitz MC et al. | How B cells influence bone biology in health and disease. | 2010 | Bone | pmid:20601290 |
| Uemura H et al. | Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover. | 2003 | Bone | pmid:14623063 |
| Pobeha P et al. | Relationship between osteoporosis and adipose tissue leptin and osteoprotegerin in patients with chronic obstructive pulmonary disease. | 2011 | Bone | pmid:21376149 |
| Kido S et al. | Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. | 2003 | Bone | pmid:12810169 |
| Yasuda H et al. | A novel molecular mechanism modulating osteoclast differentiation and function. | 1999 | Bone | pmid:10423033 |
| Wada N et al. | Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. | 2004 | Bone | pmid:15336598 |
| Han X et al. | Effects of cod bone gelatin on bone metabolism and bone microarchitecture in ovariectomized rats. | 2009 | Bone | pmid:19124090 |
| Amato G et al. | High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. | 2004 | Bone | pmid:15336617 |
| Wuyts W et al. | Evaluation of the role of RANK and OPG genes in Paget's disease of bone. | 2001 | Bone | pmid:11165949 |
| Matsuzaki E et al. | Sphingosine-1-phosphate promotes the nuclear translocation of β-catenin and thereby induces osteoprotegerin gene expression in osteoblast-like cell lines. | 2013 | Bone | pmid:23612487 |
| Nagae M et al. | Osteoclasts play a part in pain due to the inflammation adjacent to bone. | 2006 | Bone | pmid:16769263 |
| Shin HH et al. | Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells. | 2006 | Bone | pmid:16750437 |
| Kennedy OD et al. | Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. | 2012 | Bone | pmid:22342796 |
| Kiviranta R et al. | Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. | 2005 | Bone | pmid:15664014 |
| Tat SK et al. | OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. | 2006 | Bone | pmid:16750945 |
| Liu D and Wise GE | A DNA microarray analysis of chemokine and receptor genes in the rat dental follicle--role of secreted frizzled-related protein-1 in osteoclastogenesis. | 2007 | Bone | pmid:17540629 |
| Stilgren LS et al. | Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. | 2004 | Bone | pmid:15207766 |
| Tsangari H et al. | Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. | 2004 | Bone | pmid:15207775 |
| Franklin M et al. | Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway. | 2006 | Bone | pmid:16890505 |
| Li X et al. | Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. | 2009 | Bone | pmid:19539794 |
| Martini G et al. | Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. | 2007 | Bone | pmid:16979395 |
| Kim CH et al. | Oscillatory fluid flow-induced shear stress decreases osteoclastogenesis through RANKL and OPG signaling. | 2006 | Bone | pmid:16860618 |
| Jacquin C et al. | Macrophage migration inhibitory factor inhibits osteoclastogenesis. | 2009 | Bone | pmid:19591967 |
| Itonaga I et al. | Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. | 2004 | Bone | pmid:14751563 |
| Tanaka M et al. | Alteration of Dickkopf-1 and receptor activator of nuclear factor-κB ligand during PBSC mobilization in healthy donors by G-CSF. | 2012 | Bone Marrow Transplant. | pmid:22120987 |
| Estanislau IM et al. | Pleiotropic effects of statins on the treatment of chronic periodontitis--a systematic review. | 2015 | Br J Clin Pharmacol | pmid:25444240 |
| Mackie PS et al. | Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. | 2001 | Br. J. Cancer | pmid:11286476 |
| Beuselinck B et al. | RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. | 2015 | Br. J. Cancer | pmid:26528707 |
| Lau YS et al. | Malignant melanoma and bone resorption. | 2006 | Br. J. Cancer | pmid:16641914 |
| Lau YS et al. | Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma. | 2007 | Br. J. Cancer | pmid:17533390 |
| Pepe J et al. | Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. | 2006 | Br. J. Haematol. | pmid:16848794 |
| Haaber J et al. | Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. | 2008 | Br. J. Haematol. | pmid:18005268 |
| Magal I et al. | Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease. | 2006 | Br. J. Haematol. | pmid:16512834 |
| Shalhoub V et al. | Characterization of osteoclast precursors in human blood. | 2000 | Br. J. Haematol. | pmid:11122091 |
| Terpos E et al. | New insights into the pathophysiology and management of bone disease in multiple myeloma. | 2003 | Br. J. Haematol. | pmid:14632767 |
| Chollet ME et al. | Evidence of a colocalisation of osteoprotegerin (OPG) with von Willebrand factor (VWF) in platelets and megakaryocytes alpha granules. Studies from normal and grey platelets. | 2010 | Br. J. Haematol. | pmid:19958354 |
| Terpos E et al. | Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. | 2006 | Br. J. Haematol. | pmid:17107351 |
| Voskaridou E et al. | Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. | 2003 | Br. J. Haematol. | pmid:14616979 |
| Politou M et al. | Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). | 2004 | Br. J. Haematol. | pmid:15327520 |
| Depil S et al. | Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma. | 2005 | Br. J. Haematol. | pmid:15916694 |
| Bord S et al. | Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. | 2004 | Br. J. Haematol. | pmid:15238146 |
| Roux S et al. | RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. | 2002 | Br. J. Haematol. | pmid:11918537 |
| Bock O et al. | Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin. | 2005 | Br. J. Haematol. | pmid:15982347 |
| Chen WF et al. | Total flavonoid fraction of the Herba epimedii extract suppresses urinary calcium excretion and improves bone properties in ovariectomised mice. | 2011 | Br. J. Nutr. | pmid:20815976 |
| Zhao H et al. | Long-term resveratrol treatment prevents ovariectomy-induced osteopenia in rats without hyperplastic effects on the uterus. | 2014 | Br. J. Nutr. | pmid:24073920 |
| Karieb S and Fox SW | Zinc modifies the effect of phyto-oestrogens on osteoblast and osteoclast differentiation in vitro. | 2012 | Br. J. Nutr. | pmid:22289672 |
| Zhang Y et al. | Erythrina variegata extract exerts osteoprotective effects by suppression of the process of bone resorption. | 2010 | Br. J. Nutr. | pmid:20487580 |
| Hooshmand S et al. | The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial. | 2014 | Br. J. Nutr. | pmid:24780728 |
| Chen WF and Wong MS | Genistein modulates the effects of parathyroid hormone in human osteoblastic SaOS-2 cells. | 2006 | Br. J. Nutr. | pmid:16768824 |
| Wong KC et al. | Drynaria fortunei-derived total flavonoid fraction and isolated compounds exert oestrogen-like protective effects in bone. | 2013 | Br. J. Nutr. | pmid:23302510 |
| Mok SK et al. | Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. | 2010 | Br. J. Pharmacol. | pmid:20128811 |
| Brennan TC et al. | Osteoblasts play key roles in the mechanisms of action of strontium ranelate. | 2009 | Br. J. Pharmacol. | pmid:19563530 |
| Michael H et al. | Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. | 2007 | Br. J. Pharmacol. | pmid:17420779 |
| Liu W et al. | Polymorphisms in three genes are associated with hemorrhagic stroke. | 2015 | Brain Behav | pmid:26664786 |
| Petri AD et al. | Effects of low-level laser therapy on human osteoblastic cells grown on titanium. | 2010 | Braz Dent J | pmid:21271038 |
| Tera Tde M et al. | The RANK/ RANKL/ OPG interaction in the repair of autogenous bone grafts in female rats with estrogen deficiency. | 2014 | Braz Oral Res | pmid:25229791 |
| Zhang L et al. | Effects of IL-10 and glucose on expression of OPG and RANKL in human periodontal ligament fibroblasts. | 2016 | Braz. J. Med. Biol. Res. | pmid:27074164 |
| Taveira AT et al. | Longitudinal evaluation of hepatic osteodystrophy in children and adolescents with chronic cholestatic liver disease. | 2010 | Braz. J. Med. Biol. Res. | pmid:21049245 |
| Nascimento MM et al. | Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease. | 2014 | Braz. J. Med. Biol. Res. | pmid:25296363 |
| Bezerra MC et al. | RANK, RANKL and osteoprotegerin in arthritic bone loss. | 2005 | Braz. J. Med. Biol. Res. | pmid:15785827 |
| Mariúba MV et al. | Effect of triiodothyronine on the maxilla and masseter muscles of the rat stomatognathic system. | 2011 | Braz. J. Med. Biol. Res. | pmid:21584440 |
| Rachner TD et al. | Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. | 2014 | Breast Cancer Res. | pmid:24528599 |
| Canon J et al. | RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. | 2012 | Breast Cancer Res. Treat. | pmid:22926264 |
| Holen I et al. | Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival? | 2005 | Breast Cancer Res. Treat. | pmid:16155791 |
| Jacot W et al. | Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. | 2012 | Breast Cancer Res. Treat. | pmid:22562178 |
| Neville-Webbe HL et al. | Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. | 2004 | Breast Cancer Res. Treat. | pmid:15567943 |
| Bénard J | [From metastatic osteolysis a painful message: beginning to understand with osteoprotegerin? | 2000 | Bull Cancer | pmid:11184451 |
| Clézardin P | [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications]. | 2011 | Bull Cancer | pmid:21700551 |
| Sawajiri M et al. | Different effects of carbon ion and gamma-irradiation on expression of receptor activator of NF-kB ligand in MC3T3-E1 osteoblast cells. | 2006 | Bull. Exp. Biol. Med. | pmid:17415477 |
| Stilgren LS et al. | Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. | 2003 | Calcif. Tissue Int. | pmid:14667132 |
| Padagas J et al. | The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. | 2006 | Calcif. Tissue Int. | pmid:16362459 |
| Ma H et al. | Effects of diet-induced obesity and voluntary wheel running on bone properties in young male C57BL/6J mice. | 2010 | Calcif. Tissue Int. | pmid:20229059 |
| Liu JM et al. | Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. | 2005 | Calcif. Tissue Int. | pmid:15455183 |
| Frost ML et al. | Relationship of calcification of atherosclerotic plaque and arterial stiffness to bone mineral density and osteoprotegerin in postmenopausal women referred for osteoporosis screening. | 2008 | Calcif. Tissue Int. | pmid:18612580 |
| Kimura M et al. | Bisphosphonate treatment increases the size of the mandibular condyle and normalizes growth of the mandibular ramus in osteoprotegerin-deficient mice. | 2008 | Calcif. Tissue Int. | pmid:18183447 |
| Lossdörfer S et al. | Immunohistochemical localization of receptor activator of nuclear factor kappaB (RANK) and its ligand (RANKL) in human deciduous teeth. | 2002 | Calcif. Tissue Int. | pmid:12043011 |
| Wynne F et al. | Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. | 2002 | Calcif. Tissue Int. | pmid:12073153 |
| Choi JY et al. | Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women. | 2005 | Calcif. Tissue Int. | pmid:16151677 |
| Ulrich-Vinther M and Andreassen TT | Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. | 2005 | Calcif. Tissue Int. | pmid:15812581 |
| Cibulka R et al. | Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients. | 2007 | Calcif. Tissue Int. | pmid:17622482 |
| Eslami B et al. | Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. | 2011 | Calcif. Tissue Int. | pmid:21327765 |